Authors
Loading...
In vitro study uncovers preferential butyrylcholinesterase inhibition by thiosemicarbazone-carbamates in enzyme assays, highlighting their potential for Alzheimer's disease treatment.
Sellitepe et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: